Viral vectors as vaccine platforms: from immunogenicity to impact.

Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol. 2016 Jun 7;41:47-54 Authors: Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L Abstract Viral vectors are the vaccine platform of choice for many pathogens that have thwarted efforts towards control using conventional vaccine approaches. Although the STEP trial encumbered development of recombinant human adenovirus vectors only a few years ago, replication-deficient simian adenoviruses have since emerged as a crucial component of clinically effective prime-boost regimens. The vectors discussed here elicit functionally relevant cellular and humoral immune responses, at extremes of age and in diverse populations. The recent Ebola virus outbreak highlighted the utility of viral vectored vaccines in facilitating a rapid response to public health emergencies. Meanwhile, technological advances in manufacturing to support scale-up of viral vectored vaccines have helped to consolidate their position as a leading approach to tackling 'old' and emerging infections. PMID: 27286566 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research

Related Links:

New research coming out of Durham could increase the effectiveness of a cocaine vaccine that blocks the illicit drug's effect – giving promise for therapeutic applications to help recovery. According to a new study by Duke University researchers, published in the journal npj Vaccines, a new formulation tested in mice has effectively negated the effects of cocaine. The drug works by pushing the body's immune system to c reate antibodies to respond against cocaine. The mice studies, according to…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
No abstract available
Source: AJN - Category: Nursing Tags: In the News Source Type: research
Publication date: Available online 20 February 2020Source: Neurología (English Edition)Author(s): J.A. Crespo Burillo, Á. Gimenez Muñoz, J.M. Pérez Trullén
Source: Neurologia - Category: Neurology Source Type: research
More than 21 people have died from coronavirus, mostly in China. Now, a group of Americans evacuees, released from federal quarantine, were bussed to airports in California. Carter Evans has the latest.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
Even as illnesses and deaths from the new virus increase, fear is advancing like a tsunami, and not just around the Chinese city of Wuhan, the center of the outbreak that has been declared a global health emergency
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Abstract Despite the fact that there had been multiple small outbreaks of Ebola Virus Disease, when a large outbreak occurred in 2014 there were no vaccines or drugs available for use. Clinical development of multiple candidate vaccines was then initiated in parallel with attempts to contain the outbreak but only one vaccine was eventually tested in a phase III trial. In order to be better prepared for future outbreaks of known human pathogens, platform technologies to accelerate vaccine development should be employed, allowing vaccine developers to take advantage of detailed knowledge of the vaccine platform and ...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
The 2013 –16 epidemic of Ebola virus disease in west Africa was a game changer—not only in terms of the location and dimension of the outbreak and with regards to many painful lessons learnt about the epidemiology, features, and management of the disease, but also in terms of furthering the development o f monoclonal antibody treatments1,2 and, most importantly, vaccines. Besides the replicative vector-based rVSV-ZEBOV vaccine,3,4 which has yielded high efficacy in an interim analysis of an open-label, cluster-randomised ring vaccination trial in Guinea,5 a range of other candidate vaccines have pro gressed int...
Source: LANCET - Category: Journals (General) Authors: Tags: Comment Source Type: research
Background: The 2014 outbreak of Ebola haemorrhagic fever (EHF) has claimed> 11,000 lives. No vaccines or antivirals are available for EHF, but are currently the subject of intense investigations. Several vaccines targeting the Ebola virus glycoprotein (GP) are currently under different phases of clinical testing, where GP is delivered through chimpanzee adenovirus (Ad) 3 (GlaxoSmithKline), vesicular stomatitis virus (Merck), human Ad26 and35 (Johnson &Johnson) or human Ad5 (Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Type: Poster Presentation Source Type: research
Abstract The 2014 Ebola virus outbreak caused an order of magnitude more deaths in a single outbreak than all previous known outbreaks combined, affecting both local and international public health, and threatening the security and economic stability of the countries in West Africa directly confronting the outbreak. The severity of the epidemic lead to a global response to assist with patient care, outbreak control, and deployment of vaccines. The latter was possible due to the long history of basic and clinical research aimed at identifying a safe and effective vaccine to protect against Ebola virus infection. Th...
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research
Publication date: Available online 25 March 2015 Source:The Lancet Author(s): Feng-Cai Zhu , Li-Hua Hou , Jing-Xin Li , Shi-Po Wu , Pei Liu , Gui-Rong Zhang , Yue-Mei Hu , Fan-Yue Meng , Jun-Jie Xu , Rong Tang , Jin-Long Zhang , Wen-Juan Wang , Lei Duan , Kai Chu , Qi Liang , Jia-Lei Hu , Li Luo , Tao Zhu , Jun-Zhi Wang , Wei Chen Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain...
Source: The Lancet - Category: Journals (General) Source Type: research
More News: Adenoviruses | Allergy & Immunology | Ebola | Ebola Vaccine | Emergency Medicine | Health | International Medicine & Public Health | Outbreaks | Vaccines